Daniel J. O'Connor
CIK 1376847 · President and CEO · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
8
Total Filings
88
Lifetime Open-Market Net
-$845.8K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DMAC | Director | 0 | $6.64 | $0 | $0 | 2 | 2026-06-03 |
| Ambrx Biopharma, Inc. (AMAM) Delisted | President and CEO | 0 | $28.00 | $0 | -$491.1K | 5 | 2024-03-07 |
| SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Director | 4 | $0.39 | $2 | $9.8K | 7 | 2024-01-08 |
| ZyVersa Therapeutics, Inc. (LSPRW) Delisted | Chief Executive Officer | 42,005 | $0.18 | $7.6K | $0 | 1 | 2022-03-10 |
| ONCOSEC MEDICAL Inc (ONCS) Delisted | CEO and President | 4,368 | $0.28 | $1.2K | -$48.5K | 18 | 2021-05-04 |
| Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Chief Executive Officer | 618,352 | — | — | -$68.6K | 11 | 2017-07-03 |
| Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | Chief Executive Officer | 302,710 | — | — | -$247.4K | 39 | 2016-10-04 |
| IMCLONE SYSTEMS INC (IMCL) Delisted | SVP, Interim Gen. Counsel, Sec | — | — | — | $0 | 2 | 2007-02-21 |
Recent Filings · Page 4 of 9
88 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-05-07 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-02-06 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Buy (P) | +16,667 | $25.0K | EDGAR |
| 2018-01-17 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-09-11 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-03 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Grant (A) | +742 | $4.8K | EDGAR |
| 2017-06-20 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Grant (A) | +177,102 | $0 | EDGAR |
| 2017-06-01 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Grant (A) | +421 | $3.4K | EDGAR |
| 2017-05-01 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Grant (A) | +143,345 | $3.0K | EDGAR |
| 2017-04-03 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Grant (A) | +365 | $3.0K | EDGAR |
| 2017-03-01 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Mixed | +386 | $3.4K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.